Profund Advisors’s Design Therapeutics DSGN Stock Holding History

Profund Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$180K	Buy	+14,351	New	+$198K	0.01%	1033

Other funds holding DSGN

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

Profund Advisors's DSGN Position: Q3 2026 in Review

Profund Advisors opened a new position in Design Therapeutics (DSGN) in Q3 2026: 14,351 shares worth $180K. The stake represents 0.01% of the portfolio and ranks #1033 among its holdings.

23 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

Profund Advisors held 14,351 shares of Design Therapeutics worth $180K as of Q3 2026.
Design Therapeutics was a new Profund Advisors position in Q3 2026.
Design Therapeutics made up 0.01% of Profund Advisors's portfolio in Q3 2026, its #1033 holding.
23 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.